Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.
Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E, Valente S, Giglioli C, Fedi S, Gensini GF, Abbate R, Prisco D. Paniccia R, et al. Among authors: valente s. Am J Clin Pathol. 2007 Jul;128(1):143-9. doi: 10.1309/0G1PEJ00J8KP8357. Am J Clin Pathol. 2007. PMID: 17580282
Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment.
Giusti B, Gori AM, Marcucci R, Sestini I, Saracini C, Paniccia R, Poli S, Giglioli C, Valente S, Prisco D, Gensini GF, Abbate R. Giusti B, et al. Among authors: valente s. Atherosclerosis. 2008 Jan;196(1):341-348. doi: 10.1016/j.atherosclerosis.2006.11.009. Epub 2006 Dec 8. Atherosclerosis. 2008. PMID: 17157856
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF. Giusti B, et al. Among authors: valente s. Pharmacogenet Genomics. 2007 Dec;17(12):1057-64. doi: 10.1097/FPC.0b013e3282f1b2be. Pharmacogenet Genomics. 2007. PMID: 18004210
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Marcucci R, et al. Among authors: valente s. Circulation. 2009 Jan 20;119(2):237-42. doi: 10.1161/CIRCULATIONAHA.108.812636. Epub 2008 Dec 31. Circulation. 2009. PMID: 19118249
Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy.
Cecchi E, Marcucci R, Paniccia R, Bandinelli B, Valente S, Giglioli C, Lazzeri C, Gensini GF, Abbate R, Mannini L. Cecchi E, et al. Among authors: valente s. Am J Cardiol. 2009 Sep 15;104(6):764-8. doi: 10.1016/j.amjcard.2009.05.005. Epub 2009 Jul 18. Am J Cardiol. 2009. PMID: 19733708
High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Marcucci R, et al. Among authors: valente s. Thromb Haemost. 2010 Aug;104(2):279-86. doi: 10.1160/TH10-01-0007. Epub 2010 May 27. Thromb Haemost. 2010. PMID: 20508896
1,136 results